Curis Lifesciences Ltd vs Sanjivani Paranteral Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Curis Lifesciences Ltd is ₹ 116.5 as of 06 May 15:30 . The P/E Ratio of Curis Lifesciences Ltd is 0 as of March 2024 .The P/E Ratio of Sanjivani Paranteral Ltd is 28.4 as of March 2024 . The Market Cap of Curis Lifesciences Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Sanjivani Paranteral Ltd is ₹ 175.32 crore as of March 2024 . The revenue of Curis Lifesciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 22.36 crore as compare to the Sep '25 revenue of ₹ 15.66 crore. This represent the growth of 42.78% The ebitda of Curis Lifesciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sanjivani Paranteral Ltd for the Dec '25 is ₹ 4.13 crore as compare to the Sep '25 ebitda of ₹ 2.41 crore. This represent the growth of 71.37% The net profit of Curis Lifesciences Ltd changed from ₹ 1.2 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of -100.00% The net profit of Sanjivani Paranteral Ltd changed from ₹ 1.71 crore to ₹ 2.78 crore over 7 quarters. This represents a CAGR of 32.01% The Dividend Payout of Curis Lifesciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sanjivani Paranteral Ltd changed from 7.33 % on March 2025 to 7.33 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Curis Lifesciences Ltd

Curis Lifesciences Limited was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 in the name and style of 'M/s Loreto Pharmaceutacals', pursuant to a Deed of Partnership dated 2 June, 2010.
Thereafter ' M/s Loreto Pharmaceutacals' was converted from Partnership Firm to a Private Limited Company as 'Curis Lifesciences Private Limited' and received a Certificate of Incorporation dated on March 23rd, 2016 issued by Registrar of Companies, Ahmedabad.
Subsequently, Company was converted into a Public Limited Company and the name of the Company was changed from 'Curis Lifesciences Private Limited' to 'Curis Lifesciences Limited' vide certified incorporated upon the conversion dated August 9, 2024, issued by the Central Processing Centre, Manesar. Company's business is related to manufacturing of pharmaceutical products for different markets globally as well as domestic.

About Sanjivani Paranteral Ltd

Sanjivani Paranteral Limited is a WHO-GMP certified core pharmaceutical company and a pioneer in the manufacturing of injectables and oral solids with an extensive experience spanning two-and-a-half-decades.
The Company primarily focus on life-saving drugs and has exports to over 25 countries, while catering to the needs of a vast geographic area through two WHO-GMP certified manufacturing facilities in Mumbai and Dehradun. Incorporated as a Public Limited Company in October, 1994, Sanjivani Parenteral was jointly promoted by Anami H Khemka and a team of professionals in various fields of pharmaceutical industry.
The Company is involved in the manufacturing of pharmaceutical medicines.
Its products includes oral solids, small volume parenteral and sterile powder formulations. The company is setting up a plant at Taloja, Maharashtra, to manufacture high grade anti-biotics and life saving injectibles used in various infections, pre- and post-operative.

FAQs for the comparison of Curis Lifesciences Ltd and Sanjivani Paranteral Ltd

Which company has a larger market capitalization, Curis Lifesciences Ltd or Sanjivani Paranteral Ltd?

Market cap of Curis Lifesciences Ltd is 94 Cr while Market cap of Sanjivani Paranteral Ltd is 204 Cr

What are the key factors driving the stock performance of Curis Lifesciences Ltd and Sanjivani Paranteral Ltd?

The stock performance of Curis Lifesciences Ltd and Sanjivani Paranteral Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Curis Lifesciences Ltd and Sanjivani Paranteral Ltd?

As of May 6, 2026, the Curis Lifesciences Ltd stock price is INR ₹116.5. On the other hand, Sanjivani Paranteral Ltd stock price is INR ₹166.1.

How do dividend payouts of Curis Lifesciences Ltd and Sanjivani Paranteral Ltd compare?

To compare the dividend payouts of Curis Lifesciences Ltd and Sanjivani Paranteral Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.